Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The newly certified kits are designed for early detection and large-scale screening programs
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Company to launch product after the expiry of semaglutide patent in India
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The partnership initially will focus on cardiovascular and kidney diseases
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Subscribe To Our Newsletter & Stay Updated